One_CD day_NN ..._: Every_DT day_NN more_RBR than_IN 27,000_CD people_NNS are_VBP diagnosed_VBN with_IN cancer_NN ..._: over_IN 2,600_CD people_NNS in_IN the_DT USA_NNP die_VB from_IN heart_NN disease_NN ..._: about_IN 100,000_CD young_JJ people_NNS become_VBP addicted_VBN to_TO tobacco_NN more_JJR than_IN 3,000_CD children_NNS in_IN Africa_NNP die_NN of_IN malaria_NN globally_RB ,_, more_JJR than_IN 8,000_CD people_NNS die_VBP from_IN AIDS_NNP ._.
Products_NNPS for_IN the_DT future_NN in_IN key_JJ disease_NN areas_NNS One_CD day_NN statistics_NNS such_JJ as_IN Diabetes_NNP A_NNP new_JJ concept_NN featuring_VBG a_DT PPAR_NNP pan_VB agonist_NN ._.
677954_CD ,_, an_DT Avandia_NNP followthese_NN will_MD not_RB be_VB as_IN bleak_JJ ._.
Tona_NNP Gilmer_NNP is_VBZ on_IN a_DT path_NN to_TO a_DT up_RB ,_, promises_VBZ glucose_NN and_CC lipid_JJ day_NN she_PRP hopes_VBZ will_MD see_VB more_JJR cures_NNS for_IN control_NN without_IN weight_NN gain_NN cancer_NN ._.
For_IN 15_CD years_NNS ,_, Tona_NNP has_VBZ been_VBN and_CC fluid_JJ retention_NN ._.
GSK_NNP is_VBZ playing_VBG a_DT leading_VBG working_NN in_IN oncology_JJ research_NN ,_, seeking_VBG Malaria_NN In_IN 2003_CD we_PRP launched_VBD better_JJR ways_NNS to_TO treat_VB cancer_NN with_IN a_DT passion_NN a_DT new_JJ anti-malarial_JJ ,_, Lapdap_NNP ,_, and_CC commitment_NN borne_VBN from_IN knowing_VBG and_CC we_PRP now_RB have_VBP two_CD early_JJ that_IN so_RB many_JJ people_NNS are_VBP or_CC have_VBP been_VBN malaria_NN compounds_NNS in_IN part_NN in_IN tackling_VBG these_DT global_JJ affected_VBN by_IN the_DT disease_NN ._.
We_PRP are_VBP also_RB developing_VBG vaccines_NNS against_IN My_PRP$ mother_NN was_VBD extremely_RB ill_JJ when_WRB I_PRP diseases_NNS of_IN the_DT developing_VBG was_VBD a_DT baby_NN and_CC ,_, as_IN I_PRP grew_VBD up_RB ,_, I_PRP wanted_VBD challenges_NNS ,_, constantly_RB world_NN ._.
One_CD example_NN is_VBZ so_RB much_JJ to_TO know_VB what_WP causes_VBZ illness_NN Mosquirix_NNP ,_, which_WDT has_VBZ and_CC why_WRB there_EX are_VBP so_RB few_JJ effective_JJ demonstrated_VBN clinical_JJ proof_NN treatments_NNS ._.
Today_NN ,_, as_IN director_NN of_IN of_IN concept_NN in_IN a_DT field_NN efficacy_NN striving_VBG to_TO make_VB the_DT world_NN Oncology_NNP Biology_NNP at_IN Research_NNP Triangle_NNP trial_NN in_IN Africa_NNP ._.
Park_NNP in_IN the_DT USA_NNP ,_, Tona_NNP and_CC her_PRP$ team_NN of_IN Heart_NNP disease_NN GSK_NNP has_VBZ about_RB 30_CD scientists_NNS are_VBP playing_VBG a_DT key_JJ role_NN a_DT number_NN of_IN projects_NNS in_IN a_DT healthier_RBR place_NN ._.
in_IN GSKs_NNS efforts_NNS to_TO find_VB these_DT treatments_NNS ._.
cardiovascular_JJ research_NN that_WDT hold_VBP the_DT prospect_NN of_IN I_PRP have_VBP never_RB lost_VBN sight_NN of_IN the_DT bigger_JJR significantly_RB improving_VBG picture_NN -_: the_DT patients_NNS -_: in_IN the_DT detail_NN of_IN my_PRP$ treatment_NN options_NNS ._.
A_DT novel_NN We_PRP are_VBP now_RB beginning_VBG to_TO see_VB implicated_VBN in_IN breast_NN cancer_NN and_CC GSKs_NNS bold_JJ and_CC creative_JJ new_JJ R&D_NNP work_NN because_IN its_PRP$ very_RB personal_JJ ._.
class_NN of_IN compounds_NNS targets_VBZ the_DT benefits_NNS of_IN our_PRP$ innovative_JJ other_JJ solid_JJ tumors_NNS and_CC may_MD help_VB model_NN is_VBZ working_VBG and_CC the_DT company_NN While_IN much_JJ progress_NN has_VBZ been_VBN made_VBN ,_, a_DT newly_RB identified_VBN risk_NN factor_NN restructuring_NN of_IN the_DT R&D_NNP process_NN convert_VBP the_DT management_NN of_IN some_DT is_VBZ developing_VBG more_JJR quality_NN for_IN heart_NN disease_NN ,_, an_DT enzyme_NN the_DT end_NN of_IN Tonas_NNP path_NN remains_VBZ unclear_JJ ._.
As_IN a_DT result_NN cancers_NNS to_TO chronic_JJ stable_JJ disease_NN compounds_NNS than_IN ever_RB before_RB ._.
These_DT Perhaps_RB as_IN we_PRP search_VBP for_IN clues_NNS to_TO a_DT cure_NN ,_, of_IN dramatically_RB improved_VBN rates_NNS of_IN states_NNS ._.
inhibitors_NNS sharply_RB lower_JJR the_DT productivity_NN ,_, the_DT whole_JJ span_NN of_IN our_PRP$ That_DT has_VBZ to_TO be_VB good_JJ news_NN for_IN we_PRP can_MD treat_VB cancer_NN in_IN a_DT way_NN that_IN activity_NN of_IN this_DT enzyme_NN in_IN pipeline_NN is_VBZ strong_JJ and_CC bursting_VBG with_IN In_IN phase_NN I_PRP studies_NNS among_IN patients_NNS patients_NNS around_IN the_DT world_NN waiting_VBG becomes_VBZ more_JJR like_IN treating_VBG chronic_JJ atherosclerotic_JJ plaque_NN ,_, which_WDT potential_NN ._.
Where_WRB once_RB a_DT disease_NN who_WP had_VBD failed_VBN multiple_JJ prior_RB for_IN new_JJ and_CC better_RBR treatments_NNS in_IN diseases_NNS ._.
GSKs_NNS compound_VBP in_IN is_VBZ expected_VBN to_TO reduce_VB was_VBD thought_VBN to_TO be_VB untreatable_JJ ,_, treatments_NNS with_IN other_JJ drugs_NNS ,_, 46_CD many_JJ major_JJ diseases_NNS and_CC illnesses_NNS ._.
development_NN ,_, 572016_CD ,_, is_VBZ hopefully_RB one_CD inflammation_NN in_IN arterial_JJ walls_NNS ._.
modern_JJ day_NN research_NN will_MD provide_VB per_IN cent_NN of_IN breast_NN cancer_NN patients_NNS such_JJ treatment_NN ._.
So_RB far_RB the_DT results_NNS are_VBP hope_NN for_IN sufferers_NNS ._.
treated_VBN with_IN 572016_CD showed_VBD either_CC extremely_RB encouraging_JJ ._.
We_PRP have_VBP huge_JJ a_DT partial_JJ response_NN or_CC stable_JJ disease_NN ._.
hopes_NNS for_IN it_PRP and_CC maybe_RB the_DT future_NN will_MD One_CD of_IN the_DT compounds_NNS featured_VBD see_VB an_DT even_RB better_JJR 572016_CD ._.
on_IN this_DT page_NN is_VBZ a_DT first_JJ of_IN its_PRP$ kind_NN ._.
Each_DT On_IN a_DT December_NNP day_NN in_IN 1998_CD ,_, the_DT full_JJ The_DT investigational_JJ compound_NN ,_, and_CC every_DT day_NN ,_, GSK_NNP spends_VBZ nearly_RB 572016_CD ,_, is_VBZ a_DT dual_JJ kinase_NN inhibitor_NN 8_CD million_CD in_IN research_NN for_IN future_JJ number_NN of_IN this_DT compound_NN was_VBD scrawled_VBN being_VBG studied_VBN for_IN the_DT treatment_NN of_IN therapies_NNS therapies_NNS that_WDT will_MD on_IN a_DT whiteboard_NN in_IN Tonas_NNP office_NN by_IN a_DT solid_JJ tumors_NNS ._.
provide_VB hope_NN for_IN millions_NNS of_IN people_NNS ._.
This_DT is_VBZ it_PRP -_: this_DT is_VBZ the_DT one_CD ,_, he_PRP said_VBD ._.
It_PRP is_VBZ a_DT daily_JJ oral_JJ therapy_NN under_IN Im_NNP never_RB going_VBG to_TO remove_VB it_PRP ,_, said_VBD investigation_NN for_IN advanced_JJ breast_NN Tona_NNP ._.
moment_NN and_CC cancer_NN ,_, non-small_JJ cell_NN lung_NN ,_, bladder_NN ,_, part_NN of_IN the_DT excitement_NN of_IN our_PRP$ work_NN ,_, all_DT of_IN gastric_JJ and_CC head_NN and_CC neck_NN cancers_NNS ._.
which_WDT is_VBZ such_JJ a_DT great_JJ opportunity_NN to_TO help_VB It_PRP blocks_VBZ two_CD of_IN the_DT kinases_NNS answer_VB the_DT sort_NN of_IN questions_NNS I_PRP have_VBP had_VBN for_IN so_RB long_JJ ._.
